Literature DB >> 15034230

Effects of zolpidem and zaleplon on sleep, respiratory patterns and performance at a simulated altitude of 4,000 m.

Maurice Beaumont1, Denise Batéjat, Olivier Coste, Pascal Van Beers, Anthony Colas, Jean-Michel Clère, Christophe Piérard.   

Abstract

The effects of zolpidem or zaleplon on sleep architecture, respiratory patterns and performance were assessed at a simulated altitude of 4,000 m. Twelve male healthy subjects spent 4 nights in a decompression chamber, 1 at sea level (baseline), 3 at 4,000 m to test zolpidem (10 mg), zaleplon (10 mg) and placebo, given 15 min before switching the lights off. Sleep and respiratory patterns were analysed using polysomnography. Cognitive and physical performance was examined the next morning at sea level conditions. The study demonstrates that both zolpidem and zaleplon improved slow wave sleep at altitude, with zolpidem showing more marked effects than zaleplon. Both agents did not adversely affect respiration at altitude during the night, or cognitive or physical performance the next morning at the dosages used in this study. Thus, climbers may safely use both hypnotic agents. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034230     DOI: 10.1159/000076723

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  15 in total

1.  A randomized trial of temazepam versus acetazolamide in high altitude sleep disturbance.

Authors:  John B Tanner; Sarah M E Tanner; Ghan Bahadur Thapa; Yuchiao Chang; Kirsty L M Watson; Eamon Staunton; Claire Howarth; Buddha Basnyat; N Stuart Harris
Journal:  High Alt Med Biol       Date:  2013-09-12       Impact factor: 1.981

2.  Lung disease at high altitude.

Authors:  Joshua O Stream; Andrew M Luks; Colin K Grissom
Journal:  Expert Rev Respir Med       Date:  2009-12       Impact factor: 3.772

3.  Effect of short-term acclimatization to high altitude on sleep and nocturnal breathing.

Authors:  Yvonne Nussbaumer-Ochsner; Justyna Ursprung; Christoph Siebenmann; Marco Maggiorini; Konrad E Bloch
Journal:  Sleep       Date:  2012-03-01       Impact factor: 5.849

Review 4.  The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses.

Authors:  R Nisha Aurora; Susmita Chowdhuri; Kannan Ramar; Sabin R Bista; Kenneth R Casey; Carin I Lamm; David A Kristo; Jorge M Mallea; James A Rowley; Rochelle S Zak; Sharon L Tracy
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

Review 5.  Comorbid insomnia in sleep-related breathing disorders: an under-recognized association.

Authors:  Suhaila E Al-Jawder; Ahmed S Bahammam
Journal:  Sleep Breath       Date:  2011-03-29       Impact factor: 2.816

6.  A nine-year follow-up study of sleep patterns and mortality in community-dwelling older adults in Taiwan.

Authors:  Hsi-Chung Chen; Tung-Ping Su; Pesus Chou
Journal:  Sleep       Date:  2013-08-01       Impact factor: 5.849

7.  Improvement of idiopathic central sleep apnea with zolpidem.

Authors:  Syed Quadri; Christopher Drake; David W Hudgel
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

8.  Are nocturnal breathing, sleep, and cognitive performance impaired at moderate altitude (1,630-2,590 m)?

Authors:  Tsogyal D Latshang; Christian M Lo Cascio; Anne-Christin Stöwhas; Mirjam Grimm; Katrin Stadelmann; Noemi Tesler; Peter Achermann; Reto Huber; Malcolm Kohler; Konrad E Bloch
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

Review 9.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Zaleplon and zolpidem objectively alleviate sleep disturbances in mountaineers at a 3,613 meter altitude.

Authors:  Maurice Beaumont; Denise Batéjat; Christophe Piérard; Pascal Van Beers; Matthieu Philippe; Damien Léger; Gustave Savourey; Jean-Claude Jouanin
Journal:  Sleep       Date:  2007-11       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.